Latest Insider Transactions at Cyclo Therapeutics, Inc. (CYTH)
This section provides a real-time view of insider transactions for Cyclo Therapeutics, Inc. (CYTH). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Cyclo Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Cyclo Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 01
2021
|
Francis Patrick Ostronic Director |
BUY
Open market or private purchase
|
Direct |
5,000
+5.09%
|
$25,000
$5.0 P/Share
|
|
Nov 19
2021
|
Francis Patrick Ostronic Director |
BUY
Open market or private purchase
|
Direct |
10,652
+5.5%
|
$53,260
$5.24 P/Share
|
|
Nov 19
2021
|
N Scott Fine Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+4.01%
|
$25,000
$5.25 P/Share
|
|
Oct 29
2021
|
Francis Patrick Ostronic Director |
BUY
Open market or private purchase
|
Direct |
1,000
+1.27%
|
$5,000
$5.9 P/Share
|
|
Sep 27
2021
|
Lise Lund Kjems Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,053
+50.0%
|
-
|
|
Sep 15
2021
|
N Scott Fine Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+4.18%
|
$30,000
$6.35 P/Share
|
|
Apr 16
2021
|
Francis Patrick Ostronic Director |
BUY
Open market or private purchase
|
Direct |
10,000
+6.33%
|
$60,000
$6.53 P/Share
|
|
Apr 12
2021
|
Francis Patrick Ostronic Director |
BUY
Open market or private purchase
|
Direct |
5,000
+6.99%
|
$35,000
$7.0 P/Share
|
|
Mar 29
2021
|
Jeffrey Tate Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
2,000
+6.86%
|
$14,000
$7.5 P/Share
|
|
Mar 29
2021
|
Francis Patrick Ostronic Director |
BUY
Open market or private purchase
|
Direct |
3,000
+2.4%
|
$21,000
$7.5 P/Share
|
|
Mar 29
2021
|
Sharon Hemond Hrynkow Chief Scientific Officer |
BUY
Open market or private purchase
|
Direct |
1,000
+5.17%
|
$7,000
$7.46 P/Share
|
|
Mar 29
2021
|
Joshua M Fine Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
50
+0.3%
|
$350
$7.4 P/Share
|
|
Mar 29
2021
|
Markus Sieger Director |
BUY
Open market or private purchase
|
Direct |
10,000
+12.88%
|
$80,000
$8.1 P/Share
|
|
Mar 05
2021
|
Randall M. Toig Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
10,000
+18.49%
|
$50,000
$5.0 P/Share
|
|
Jan 26
2021
|
Markus Sieger Director |
BUY
Open market or private purchase
|
Direct |
2,201
+3.68%
|
$13,206
$6.6 P/Share
|
|
Jan 25
2021
|
Markus Sieger Director |
BUY
Open market or private purchase
|
Direct |
7,799
+4.67%
|
$46,794
$6.3 P/Share
|
|
Jan 13
2021
|
Joshua M Fine Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+37.24%
|
-
|
|
Jan 13
2021
|
N Scott Fine Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+8.36%
|
-
|
|
Jan 13
2021
|
Jeffrey Tate Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+28.44%
|
-
|
|
Jan 13
2021
|
Sharon Hemond Hrynkow Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+36.56%
|
-
|
|
Jan 13
2021
|
Michael Eric Lisjak Chief Regulatory Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+44.64%
|
-
|
|
Dec 17
2020
|
Francis Patrick Ostronic Director |
BUY
Open market or private purchase
|
Direct |
30,000
+12.56%
|
$120,000
$4.64 P/Share
|
|
Dec 11
2020
|
N Scott Fine Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
20,000
+16.71%
|
-
|
|
Dec 11
2020
|
William S Shanahan Director |
BUY
Open market or private purchase
|
Direct |
20,000
+23.9%
|
-
|
|
Dec 11
2020
|
Randall M. Toig Director |
BUY
Open market or private purchase
|
Direct |
10,000
+22.69%
|
-
|
|
Dec 11
2020
|
Markus Sieger Director |
BUY
Open market or private purchase
|
Direct |
15,000
+17.1%
|
-
|
|
Dec 11
2020
|
Sharon Hemond Hrynkow Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,000
+11.98%
|
-
|
|
Dec 11
2020
|
Jeffrey Tate Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+24.8%
|
-
|
|
Nov 25
2020
|
Joshua M Fine Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
15,000
+2.14%
|
$0
$0.08 P/Share
|
|
Nov 23
2020
|
Joshua M Fine Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+1.47%
|
$0
$0.08 P/Share
|
|
Sep 30
2020
|
Armistice Capital, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
0
|
-
|
|
Sep 30
2020
|
Armistice Capital, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
5,500
-0.03%
|
$0
$0.13 P/Share
|
|
Sep 29
2020
|
Armistice Capital, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
0
|
-
|
|
Sep 29
2020
|
Armistice Capital, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
5,000
-0.03%
|
$0
$0.14 P/Share
|
|
Sep 28
2020
|
Armistice Capital, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
0
|
-
|
|
Sep 28
2020
|
Armistice Capital, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
4,966
-0.03%
|
$0
$0.13 P/Share
|
|
Sep 24
2020
|
Armistice Capital, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
0
|
-
|
|
Sep 24
2020
|
Armistice Capital, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
38,257
-0.24%
|
$0
$0.13 P/Share
|
|
Sep 23
2020
|
Armistice Capital, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
0
|
-
|
|
Sep 23
2020
|
Armistice Capital, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
50,000
-0.31%
|
$0
$0.14 P/Share
|
|
Sep 22
2020
|
Armistice Capital, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
0
|
-
|
|
Sep 22
2020
|
Armistice Capital, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
17,000
-0.11%
|
$0
$0.15 P/Share
|
|
Sep 21
2020
|
Armistice Capital, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
0
|
-
|
|
Sep 21
2020
|
Armistice Capital, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
100,000
-0.62%
|
$0
$0.15 P/Share
|
|
Sep 16
2020
|
Armistice Capital, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
0
|
-
|
|
Sep 16
2020
|
Armistice Capital, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
125,000
-0.77%
|
$0
$0.16 P/Share
|
|
Sep 15
2020
|
Armistice Capital, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
0
|
-
|
|
Sep 15
2020
|
Armistice Capital, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
82,084
-0.51%
|
$0
$0.16 P/Share
|
|
Sep 14
2020
|
Armistice Capital, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
0
|
-
|
|
Sep 14
2020
|
Armistice Capital, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
130,000
-0.79%
|
$0
$0.17 P/Share
|